Testicular Cancer Treatment in Germany

Testicular cancer is uncommon, but it is the cancer most often diagnosed in young men, and it responds very well to treatment. European guideline data report long-term survival above 95% across all stages combined. The outlook for any one person still depends on the tumour type, how far it has spread and how it responds to treatment.

In Germany, around 4,000 men are diagnosed each year. Treatment is led by urologists and medical oncologists who follow European Association of Urology (EAU) guidance and a national German clinical guideline. Most men start with surgery to remove the affected testicle. What happens next (surveillance, chemotherapy, radiotherapy or more surgery) depends on the findings.

Testicular cancer treatment in Germany usually begins with a radical inguinal orchiectomy. It is then tailored to the tumour type (seminoma or non-seminoma), the stage and tumour-marker blood levels. Options include active surveillance, chemotherapy, radiotherapy and retroperitoneal lymph node dissection, chosen by a multidisciplinary team. No single plan applies to every patient. 

This page focuses on adult testicular germ-cell cancers. Childhood tumours and other cancers involving the testicle may follow different pathways.

What Is Testicular Cancer?

Testicular cancer is a malignant tumour that starts in one or, rarely, both testicles. Between 90% and 95% are germ cell tumours, which arise from the cells that would normally develop into sperm.

Most germ cell tumours grow from an earlier, non-invasive change called germ cell neoplasia in situ (GCNIS). Recognised risk factors include:

• An undescended testicle (cryptorchidism), even if it was corrected in childhood
• A previous testicular cancer in the other testicle
• A father or brother who had testicular cancer

There is no evidence to support population screening. Men with these risk factors are advised to examine their testicles regularly.

Types of Testicular Cancer

After surgery, a pathologist confirms the tumour type. Type is one of the two main factors that shape treatment. The other is stage.

Seminoma

Seminoma is a germ cell tumour made up of cells that resemble early sperm-forming cells. It tends to grow more slowly and is particularly sensitive to both chemotherapy and radiation. Pure seminoma does not produce significant levels of the tumour marker alpha-fetoprotein (AFP). A clearly raised AFP suggests that non-seminoma cells are also present.

Non-seminoma

Non-seminomatous germ cell tumours (NSGCTs) include embryonal carcinoma, yolk sac tumour, choriocarcinoma and teratoma, and many tumours are mixed. Non-seminomas are more likely to raise AFP or human chorionic gonadotropin (hCG).

Teratoma needs special mention because it does not respond to chemotherapy. If teratoma remains after treatment, surgery is usually the only way to remove it.

Other Rare Testicular Tumours

A small proportion of testicular tumours are not germ cell tumours. These include sex cord-stromal tumours, such as Leydig cell and Sertoli cell tumours, which are often benign. Others are spermatocytic tumour, which mainly affects older men, and lymphoma involving the testis. They are managed differently from germ cell tumours.

Symptoms and When to Seek Medical Evaluation

The most common sign is a painless lump or swelling in one testicle. Some men notice it themselves. Others find out through an ultrasound done for another reason. Other possible signs include:

• A feeling of heaviness in the scrotum
• A dull ache in the groin or lower abdomen
• Breast tenderness or enlargement (gynaecomastia), caused by hormones some tumours produce
• Back pain, a cough or breathlessness, which can occur when the cancer has spread

Pain can make a tumour look like an infection, which sometimes delays diagnosis. Any new testicular lump that does not settle promptly should be examined by a doctor, ideally a urologist.

How Is Testicular Cancer Diagnosed in Germany?

Diagnosis combines a physical examination, ultrasound and blood tests. It is confirmed by examining the removed testicle under a microscope.

Physical Examination

The doctor examines both testicles, the abdomen, the chest and the lymph node areas above the collarbone, in the neck, armpits and groin. Enlarged nodes or breast changes can point to spread or hormone production.

Ultrasound

A high-frequency scrotal ultrasound of both testicles is the first imaging test. It confirms whether a mass lies inside the testicle and checks the other side. Scrotal MRI is reserved for unclear cases or for when testis-sparing surgery is being considered.

Blood Tests and Tumour Markers

Three blood markers are measured before and after surgery:

• AFP (alpha-fetoprotein)
• hCG (human chorionic gonadotropin)
• LDH (lactate dehydrogenase)

Raised markers support the diagnosis and hint at the tumour type. After surgery, they should fall at a predictable rate: AFP halves roughly every five to seven days, and hCG every one to three days. Levels that stay high or rise suggest the cancer has spread. Normal markers do not rule out cancer, because many tumours produce none.

A newer blood test based on microRNA-371 looks promising. It is not yet part of routine care, because testing standards and validation are still being worked out.

CT and Other Imaging

Once cancer is confirmed or strongly suspected, a contrast-enhanced CT scan of the chest, abdomen and pelvis checks for spread. MRI of the abdomen can replace CT for men who cannot receive iodine contrast. Brain MRI is added for men with multiple lung metastases, very high hCG, poor-risk disease or neurological symptoms. Current guidance advises against PET-CT and bone scans for initial staging.

Histopathology

The diagnosis is confirmed when a pathologist examines the removed testicle. The report states the tumour type and whether it has grown into nearby tissue or into blood and lymph vessels (lymphovascular invasion). These findings guide the next step.

Needle biopsy through the scrotum is avoided when cancer is suspected. It can disturb the lymphatic drainage and raise the risk of local recurrence.

How Is Testicular Cancer Staged?

Staging combines three pieces of information: the extent of the primary tumour, whether lymph nodes or distant organs are involved, and tumour-marker levels after surgery.

• Stage I: Cancer is confined to the testicle. Stage IS means imaging is clear but markers stay raised after surgery, which suggests hidden spread.
• Stage II: Cancer has reached lymph nodes at the back of the abdomen (retroperitoneal nodes). Stages IIA, IIB and IIC reflect increasing node size.
• Stage III: Cancer has spread beyond those nodes, for example to the lungs, liver, bone or brain, or marker levels are very high.

For stage IIC and III disease, doctors also use the IGCCCG prognostic groups (good, intermediate or poor risk). This International Germ Cell Cancer Collaborative Group classification weighs tumour type, sites of spread and marker levels. The risk group largely decides how much chemotherapy is given.

Testicular Cancer Treatment Options in Germany

Testicular Cancer Treatment depends mainly on tumour type, stage, marker results and whether the disease has spread or returned. Management may involve surgery, surveillance, chemotherapy, radiotherapy or further surgery, alone or in sequence. Many men with early-stage disease need nothing beyond the first operation and careful monitoring.

Surgery: Radical Inguinal Orchiectomy

Radical inguinal orchiectomy is the standard first treatment. The surgeon removes the affected testicle, together with its spermatic cord, through an incision in the groin rather than the scrotum. The operation treats the primary tumour and provides tissue for diagnosis. It is typically a short procedure with a quick recovery.

Two points are worth discussing before surgery:

• Testicular prosthesis: The 2026 EAU guideline recommends offering an artificial testicle to every man having an orchiectomy. It can be inserted during the operation or later.
• Testis-sparing surgery: Removing only the tumour may be considered when both testicles are affected, when only one testicle remains, or for small masses that are likely benign. Strict criteria apply, and the tissue is checked during the operation (frozen-section analysis).

In rare, life-threatening cases with extensive spread, chemotherapy is started before orchiectomy.

Active Surveillance

Surveillance means no further treatment after orchiectomy. Instead, the patient follows a structured schedule of scans, marker tests and clinic visits, so that any relapse is found early and treated. For many men with stage I disease, this is the option guidelines prefer. It spares most of them chemotherapy they would never have needed. Surveillance only works if appointments are kept, which matters for anyone planning treatment abroad.

Chemotherapy

Chemotherapy for germ cell tumours is platinum-based. Common regimens include:

• Carboplatin (one dose): an adjuvant option in stage I seminoma
• BEP (bleomycin, etoposide, cisplatin): the main regimen. One cycle may be given in selected stage I non-seminoma, and three to four cycles for metastatic disease.
• EP (etoposide, cisplatin): used when bleomycin is unsuitable
• VIP (etoposide, ifosfamide, cisplatin): an alternative for intermediate or poor-risk disease when bleomycin must be avoided

Each cycle usually lasts 21 days. Response is checked through falling tumour markers and repeat imaging.

Radiotherapy

Radiotherapy is now used far less than in the past because of its long-term risk of second cancers. It remains an option for some men with stage IIA or IIB seminoma, and in specific situations such as certain brain metastases. It is no longer routinely recommended after cancer surgery for stage I seminoma.

Retroperitoneal Lymph Node Dissection (RPLND)

RPLND removes lymph nodes at the back of the abdomen, where testicular cancer usually spreads first. It is used in three main settings:

• Primary RPLND: as first treatment in selected non-seminoma cases, such as marker-negative stage IIA disease, and within studies for low-volume seminoma
• Post-chemotherapy RPLND: to remove residual masses larger than 1 cm after chemotherapy for non-seminoma, which may contain teratoma or active cancer
• Salvage surgery: after relapse treatment

Nerve-sparing techniques aim to protect ejaculation. RPLND is technically demanding. Guidelines advise that it be done by experienced surgeons in specialist centres, and that minimally invasive approaches be used only in high-volume centres.

Treatment for Advanced or Metastatic Disease

Men with stage IIC or III disease receive chemotherapy based on their IGCCCG risk group. This is usually followed by surgery to remove any remaining masses. In poor-risk non-seminoma, the fall in markers after the first cycle is checked, and treatment may be intensified if the decline is too slow. Guidelines advise that poor-risk patients be treated at centres with specific germ cell tumour expertise, ideally within trials or registries. The 2026 EAU update also adds guidance on combining treatments for bone metastases.

Treatment for Relapsed or Refractory Disease

Relapse is still treatable, often with curative intent. Salvage options include:

• Cisplatin-based combinations such as VIP, TIP (paclitaxel, ifosfamide, cisplatin) or GIP (gemcitabine, ifosfamide, cisplatin)
• High-dose chemotherapy with autologous stem cell support, in which the patient's own stem cells are collected beforehand and returned afterwards
• Surgery to remove residual or resistant disease

Outcomes vary widely with prognostic factors. Because these situations are rare and complex, guidelines recommend treatment at specialised centres and, where possible, within clinical trials. Late relapse, meaning more than two years after successful treatment, is uncommon. When it occurs in non-seminoma, it is usually managed with surgery where feasible.

Testicular Cancer Treatment by Stage

The table below is a simplified overview of current EAU guidance. Actual plans are individual and agreed with the treating team.

Stage I shows why shared decision-making matters. With surveillance alone, most men never relapse. Adjuvant treatment lowers the chance of relapse further, but everyone treated is exposed to its side effects. Guidelines ask doctors to explain both paths, with their relapse rates and side effects, before the patient decides.

Fertility and Testicular Cancer Treatment

Many men with testicular cancer have not yet started or completed their families. Sperm quality is often reduced even before treatment, and chemotherapy or radiotherapy can reduce it further.

Sperm banking: Current guidance says sperm banking should be discussed with every man before treatment begins. Ideally, samples are frozen before orchiectomy, and at the latest before any chemotherapy or radiotherapy. Sperm freezing is the most established and cost-effective way to preserve fertility.

Hormones: One healthy testicle usually produces enough testosterone. Some men develop low testosterone and may need hormone replacement, particularly after treatment affecting both testicles or after intensive chemotherapy. Hormone levels are often checked during follow-up.

After treatment: Many men father children naturally after treatment. Doctors generally advise a waiting period after chemotherapy before trying to conceive, and the treating team can advise on timing.

International patients should confirm in advance that the German centre can arrange sperm cryopreservation. They should also ask how stored samples can later be transferred to a clinic in their home country.

Why Consider Germany for Testicular Cancer Treatment?

Many countries treat testicular cancer according to the same international guidelines, and the early stages are well managed in most good urology services. The case for travelling is strongest where specialist experience matters most:

• Complex surgery, especially post-chemotherapy RPLND, where guidelines link outcomes to surgeon and centre experience
• Poor-risk, relapsed or late-relapse disease, which guidelines recommend managing in specialised centres
• A second opinion on an initial treatment plan

Several features of the German system are relevant to these situations:

• A national evidence-based guideline: Germany has its own S3 guideline on testicular germ cell tumours, developed by the German Society of Urology and the German Cancer Society. A revised version (2.0) was released for public consultation in September 2026.
• Certified testicular cancer centres: The German Cancer Society (Deutsche Krebsgesellschaft, DKG) now certifies centres specifically for testicular cancer. Requirements include multidisciplinary collaboration and regular tumour boards. Certified centres can be searched on the DKG's OncoMap tool. Some experienced university departments treat many patients without holding this specific certificate.
• A second-opinion network: Since 2006, German urologists have had access to a national testicular cancer second-opinion network. A German study found that about one in six patients received more effective therapy after a second opinion.
• Multidisciplinary university hospitals: Large centres bring together urology, medical oncology, radiation oncology, pathology, radiology and reproductive medicine.
• International patient offices: Many university hospitals have departments that review records, prepare cost estimates and issue invitation letters for visa applications.

There are practical limits too. Surveillance and follow-up last for years, so a man treated in Germany will usually need a reliable follow-up arrangement closer to home. Both teams should agree on it before he leaves.

Hospitals in Germany That Treat Testicular Cancer

The hospitals below have publicly documented programmes for testicular cancer or germ cell tumours. They are listed alphabetically by city, and the order is not a ranking. Certifications are reviewed every year, so current status should be confirmed on the German Cancer Society's OncoMap before a decision is made.

Charité Universitätsmedizin Berlin

Location: Berlin
Type: University hospital

Charité's Department of Urology runs a dedicated testicular cancer centre. The team offers sperm cryopreservation before any treatment starts, and patients can discuss a testicular prosthesis. Separately, the medical oncology department has a germ cell tumour specialist clinic. Its multidisciplinary tumour board brings together oncology, urology, pathology, radiology and radiotherapy specialists.

May suit: patients who want urology and medical oncology expertise within one university hospital, and those who want fertility preservation arranged before surgery.

Helios Klinikum Bad Saarow

Location: Bad Saarow, Brandenburg (southeast of Berlin)
Type: Hospital within the Helios group

The hospital has received a German Cancer Society (DKG) certification for testicular cancer treatment, as part of its certified oncology centre.

May suit: patients looking for a certified testicular cancer centre outside a university hospital setting.

University Hospital Bonn (CIO Bonn)

Location: Bonn
Type: University hospital

The testicular cancer centre sits within the Centre for Integrated Oncology (CIO) Bonn. Its treatment quality is certified through the DKG-certified oncology centre, which also holds ISO 9001:2015 certification. CIO Bonn is part of a network with Aachen, Cologne and Düsseldorf, and the four sites follow shared protocols for testicular cancer care.

May suit: patients who want care at a certified university centre in western Germany.

University Hospital Cologne (CIO Köln)

Location: Cologne
Type: University hospital

In 2023, Cologne became one of the first centres in Germany to receive the DKG certificate specifically for testicular cancer. The centre is part of CIO Köln's uro-oncology centre. The urology department also takes part in the German Society of Urology's certified second-opinion programme for testicular cancer.

May suit: patients seeking a second opinion, and those with complex or advanced disease who want treatment at a certified testicular cancer centre.

University Hospital Freiburg (CCCF)

Location: Freiburg im Breisgau
Type: University hospital, Comprehensive Cancer Center Freiburg

Testicular cancer is treated within the Comprehensive Cancer Center Freiburg, which publishes a clinical pathway for testicular tumours. The pathway covers stage-based treatment and IGCCCG risk groups.

May suit: patients in or near southwest Germany, Switzerland or eastern France who want a structured, guideline-based treatment pathway.

University Medical Center Hamburg-Eppendorf (UKE)

Location: Hamburg
Type: University hospital

UKE runs an interdisciplinary germ cell tumour clinic shared by its urology and oncology departments. It is a recognised second-opinion centre and a member of the European Reference Network for rare adult cancers (EURACAN). For patients whose cancer does not respond adequately to first treatment, the centre offers further curative options, including high-dose chemotherapy with autologous stem cell transplantation, as well as complex surgery to remove residual tumours.

May suit: patients with relapsed, refractory or poor-risk disease, or those needing complex surgery after chemotherapy.

Ulm University Hospital

Location: Ulm
Type: University hospital, Comprehensive Cancer Center Ulm

Germ cell tumours are treated within the Comprehensive Cancer Center Ulm. Researchers from Ulm studied Germany's testicular cancer second-opinion programme and found that about one in six patients received more effective therapy after a second opinion. The hospital's international patient office prepares DRG-based cost estimates before admission.

May suit: international patients who want a clear written cost estimate before travelling, and those seeking a second opinion.

A note on choosing: For most men with early-stage testicular cancer, any well-organised urology department can provide guideline-based care. Second-opinion centres, EURACAN membership and high-dose chemotherapy programmes matter most for complex, relapsed or poor-risk cases. The "May suit" notes are there to help match a hospital to a situation, not to suggest that one hospital is better than another.

What International Patients Should Prepare

Sending complete records early speeds up the review and makes the cost estimate more accurate. Useful documents include:

• The pathology report from the orchiectomy (and, where possible, the tissue blocks or slides for review)
• All imaging reports, plus the original CT or MRI images on disc or via a download link
• Tumour-marker results (AFP, hCG, LDH) with dates, before and after surgery
• Operation notes and discharge summaries
• Details of any chemotherapy or radiotherapy: drugs, doses, number of cycles, dates and response
• A current medication list and allergies
• Other medical conditions that may affect drug choice, such as kidney, lung or hearing problems
• A passport copy, and later the hospital's invitation letter for a medical visa
• For patients from EU countries, information about the S2 form for planned treatment

Reports not in English or German may need certified translation. Ask the hospital's international office which language it accepts.

Recovery and Follow-Up

Recovery from orchiectomy is usually quick, although heavy lifting and strenuous exercise are avoided for a few weeks. Recovery from chemotherapy takes longer. Fatigue, low blood counts and a temporary drop in fertility are common. RPLND is major abdominal surgery and involves several weeks of recovery.

Follow-up is a planned part of treatment, not an optional extra. Most relapses happen within the first two years, but some occur later. Follow-up schedules usually continue for several years, and their intensity depends on the stage, tumour type and treatment received. Visits involve marker tests, imaging and physical examination. MRI can be used to reduce radiation exposure from repeated scans.

Beyond checking for relapse, long-term survivorship care looks for late effects of treatment. These can include:

• Higher cardiovascular risk, and changes in blood pressure or cholesterol
• Nerve damage causing tingling or numbness (peripheral neuropathy)
• Tinnitus or hearing loss
• Effects on kidney and lung function
• Low testosterone
• A small increase in the risk of second cancers

Anxiety and changes in body image are also common, and psychological support is part of good follow-up care.

Sources / References

Guidelines and clinical verification

1. EAU Guidelines on Testicular Cancer, 2026—full guideline. Primary reference for current management, including selected stage II seminoma surgery.
2. EAU—Diagnostic Evaluation.
3. EAU—Staging and Classification Systems.
4. EAU—Disease Management.
5. EAU—Follow-up After Curative Therapy.
6. NCI—Testicular Cancer Treatment, Health Professional PDQ.
7. NCI—Treatment by Stage.
8. ASCO—Fertility Preservation in People With Cancer: Guideline Update, 2025.
9. American Cancer Society: diagnostic tests, surgery, chemotherapy, radiotherapy, fertility and survivorship.
10. Cancer Research UK—Chemotherapy for testicular cancer.
11. NHS Essex—Testicular torsion emergency advice.

Germany-specific services and administrative verification

12. UKE—Organ Cancer Centers.
13. UKE—International Patient Process.
14. German interdisciplinary testicular tumour group—physician information and second-opinion network.
15. OncoMap—Certified Centre Directory.
16. European Commission—European Health Insurance Card.